Tamoxifen and endometrial pathologies: A prospective study

Gynecologic Oncology

Volumn 75, Issue 1, 1999, Pages 15-19

  Seoud, Muhieddine ^a   Shamseddine, Ali ^a   Khalil, Ali ^a   Salem, Ziad ^a   Saghir, Nagi ^a   Bikhazi, Kamal ^a   Bitar, Nizar ^a   Azar, Ghassan ^a   Kaspar, Hanna ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

Breast cancer; Endometrial cancer; Endometrial hyperplasia; Endometrial polyps; Screening; Tamoxifen

Indexed keywords

TAMOXIFEN;

ADULT; ARTICLE; BREAST CANCER; CONTROLLED STUDY; ENDOMETRIUM CANCER; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; POLYP; PRIORITY JOURNAL; PROSPECTIVE STUDY; VAGINA BLEEDING;

EID: 0032831797     PISSN: 00908258     EISSN: None     Source Type: Journal    
DOI: 10.1006/gyno.1999.5519     Document Type: Article

References (38)

1. Fisher B, Dignam J, Wilmark N, DeCellis A, Emir B, Wickerman L, Bryant J, Dimitrov N V, Abramson N, Atkins J N, Shibata H, Deschenes L, Morglese R G. Tamoxifen and chemotherapy for lymph node negative, estrogen receptor positive breast cancer. J Natl Cancer Inst. 88:1996;1529-1542.
2. Wickerman, D, L, Constantino, J, C, Fisher, B, Kavanah, M, Cronin, W, Vogel, V, Robidoux, A, Daly, M, Ford, L, Redmond, C, K, Wolmark, N, The initial results from NSABP protocol P-1: a clinical trial to determine the worth of tamoxifen for preventing breast cancer in women at increased risk. Proc Am Soc Clin Oncol, plenary session 3A, 1998, [Abstract].
3. Killackey M A, Hakes T B, Pierce V K. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep. 69:1985;237-238.
4. Assikis V J, Jordan V C. Gynecological effect of tamoxifen and the association with endometrial cancer. Int J Gynecol Obstet. 49:1995;241-257.
5. Assikis V J, Neven P, Jordan V C, Vergote I. A realistic clinical perspective of tamoxifen and endometrial carcinogenesis. Eur J Cancer. 32A:1996;1464-1476.
6. Seoud M A-F, Johnson J, Weed J C. Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet Gynecol. 82:1993;165-169.
7. Lathi E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen P, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol. 81:1993;660-664.
8. Gal D, Kopel S, Bashevkin M, Lebowicz J, Lev R, Tancer L. Oncologic potential of tamoxifen on endometria of postmenopausal women with breast cancer: preliminary report. Gynecol Oncol. 42:1991;120-123.
9. Gibson L E, Barakat R R, Venkatraman E S. Endometrial pathology at dilatation and curettage in breast cancer patients: comparison of tamoxifen users and nonusers. Proc Am Soc Clin Oncol. 1994;863.
10. Kedar R P, Bourne T H, Powles T J. Effects of tamoxifen on uterus and ovaries of post menopausal women in a randomized cancer prevention trial. Lancet. 343:1994;1318-1321.
11. Barakat R R, Gilewiski T A, Saigo P E. The effect of adjuvant tamoxifen on the endometrium in women with breast cancer: an interim analysis of a prospective study. Proc Am Soc Clin Oncol. 1995;779.
12. Adami H O, Kruesmo U B, Bergkvist L, Person I, Pettersson B. On the age-dependent association between cancer of the breast and endometrium. A nationwide cohort study. Br J Cancer. 55:1987;77-80.
13. Fisher B, Costantino J P, Redmond C K. Endometrial cancer in tamoxifen treated breast cancer patients. J Natl Cancer Inst. 86:1994;527-537.
14. Gourtadis M M, Robinson S P, Satyaswaroop P G, Jordan V C. Contrasting actions of tamoxifen on endometrial and breast tumor growth in the athymic mouse. Cancer Res. 48:1988;812-815.
15. Varras M, Zachos G, Spandios D A. Endometrial carcinoma in breast cancer patients treated with tamoxifen: activation of the K-ras proto-oncogene. Oncol Rep. 4:1997;1045-1046.
16. Cohen I, Beyth Y, Altaras M M, Shapira J, Tepper R, Cardoba M, Yigael D, Figer A, Fishman A, Berehein J. Estrogen and progesterone receptor expression in postmenopausal tamoxifen-exposed endometrial pathologies. Gynecol Oncol. 67:1997;8-15.
17. Elkas J, Gray K, Howard L, Petit N, Pohl J, Armstrong A. The effects of tamoxifen on endometrial insulin-like growth factor-1 expression. Obstet Gynecol. 91:1998;45-50.
18. Magriples U, Naftolin F, Schwartz P E. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol. 11:1993;485-490.
19. National Cancer Institute, SEER cancer statistics review 1973-1990, document 93-2789, Bethesda, MD, National Cancer Institute, 1993.
20. Lancet. ii:1987;171-175.
21. Fornander T, Cedermark B, Mattsson A. Adjuvant tamoxifen in early breast cancer. Occurrence of new primary cancer. Lancet. I:1989;117-119.
22. Fisher B, Dignam J, Bryant J. The worth of 5 versus more than 5 years of tamoxifen therapy for breast cancer patients with negative nodes and estrogen receptor positive tumors: an update of NSABP-14. J Natl Cancer Inst. 88:1996;1529-1542.
23. The International Agency for Research on Cancer, Feb. 1996.
24. Ismail S, Neven P, Mestagh C, van-Hoot I, Moerman P. Endometrial changes during tamoxifen treatment. Lancet. 351:1998;838.
25. Montzka P, Schultze-Mosgau A, Bauer O, Diedrich K. Eur J Cancer. 34S:1998;39.
26. Love C DB, Muir B B, McCallum J, Miller W R, Scrimgeour J B, Leonard R CP, Dixon J M. Relationship between tamoxifen duration and endometrial thickness. Breast Cancer Res Treat. 46:1997;26.
27. Fallo L, Dordoni D, Ruggeri C, Palai, Omodei U, Boccuti A M, Daldoss C. Maturotas. 27S:1997;187.
28. Cheng W H, Lin H H, Torng P L, Huang S C. Comparison of endometrial changes among symptomatic tamoxifen-treated and non-treated premenopausal and postmenopausal breast cancer patients. Gynecol Oncol. 66:1997;233-237.
29. Hann L E, Gless C S, Bach A M, Tao Y, Baum H J, Barakat R R. Endometrial thickness in tamoxifen-treated patients: correlation with clinical and pathologic findings. Am J Radiol. 168:1997;657-661.
30. Schlesinger C, Kamol S, Ascher S, Kendell M, Lage J, Silverberg S C. A comparison of endometrial polyps in patients receiving tamoxifen with two control groups. Lab Invest. 76:1997;109A.
31. Pepper J M, Oyesanya O A, Dewart P J, Howell A, Seif M W. indices of differential endometrial:myometrial growth may be used to improve the reliability of detecting endometrial neoplasia in women on tamoxifen. Ultrasound Obstet Gynecol. 8:1996;408-411.
32. Goldstein S R, Schwartz L B, Horan C, Snyder J R, Porges R F. Screening and monitering endometrial response to tamoxifen therapy for breast cancer. Menopause. 3:1996;222.
33. Goldstein S R. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol. 1/0:1994;447-451.
34. Berliere M, Charles A, Galant C, Donnez J. Uterine side effects of tamoxifen: a need for systematic pretreatment screening. Obstet Gynecol. 91:1998;40-44.
35. ACOG Committee, Opinion on tamoxifen and endometrial cancer. No. 169, February 1996.
36. Barakat R. Endometrial cancer and tamoxifen. Jordan V G. Tamoxifen: a guide for clinicians and patients. 1996.
37. Cummings, S, R, Norton, L, Eckert, S, Grady, D, Cauley, J, Knickerbocker, R, Black, D, M, Nickelson, I, Glusman, J, Krueger, K, and the, MORE investigators, Raloxifene reduces the risk of breast cancer and may decrease the risk of endometrial cancer in post-menopausal women. Two-year findings from the Multiple Outcomes of Raloxifene Evaluation (MORE) trial. Proc Am Soc Clin Oncol, plenary session, 1998, [Abstract 3].
38. Tewari K, Bonebrake R, Asrat I, Shanberg A. Ambiguous genitalia in infant exposed to tamoxifen in-utero. Lancet. 350:1997;183.